Delivery Unit from Precision RNA Medicine Core Powers New RNA-Based Cancer Therapy

In a recent Nature Communications study, Dr. Annalisa Di Ruscio and team introduced aptaDiR, a novel RNA therapeutic engineered to silence DNMT1 and reverse abnormal DNA methylation in cancer. Delivered via lipid nanoparticles, aptaDiR reactivated tumor-suppressor genes and significantly reduced tumor growth in preclinical models.

This therapeutic advance was enabled by the Delivery Unit of the Precision RNA Medicine Core at BIDMC, which prepared the GenVoy lipid nanoparticles (LNPs) used in the study.

The unit provides cutting-edge platforms for custom nucleic acid delivery, including

• LNP synthesis
• Formulation consulting
• Oligonucleotide encapsulation tailored to experimental needs

Whether you’re developing mRNA therapeutics, antisense oligos, or other RNA-based tools, the Delivery Unit offers the expertise and infrastructure to bring your project to the next stage.

Learn more about the Delivery Unit’s services
Explore all services offered by Omics Cores
Read the full study